281 related articles for article (PubMed ID: 16210086)
1. Innovative approaches to the clinical development of DNA methylation inhibitors as epigenetic remodeling drugs.
Murgo AJ
Semin Oncol; 2005 Oct; 32(5):458-64. PubMed ID: 16210086
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
3. Novel approaches on epigenetics.
Papait R; Monti E; Bonapace IM
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
[TBL] [Abstract][Full Text] [Related]
4. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies.
Lyko F; Brown R
J Natl Cancer Inst; 2005 Oct; 97(20):1498-506. PubMed ID: 16234563
[TBL] [Abstract][Full Text] [Related]
5. Epigenetics and cancer treatment.
Kristensen LS; Nielsen HM; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic alterations and cancer: new targets for therapy.
Allen A
IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis.
Vogiatzi P; Vindigni C; Roviello F; Renieri A; Giordano A
J Cell Physiol; 2007 May; 211(2):287-95. PubMed ID: 17238139
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.
Zhong S; Fields CR; Su N; Pan YX; Robertson KD
Oncogene; 2007 Apr; 26(18):2621-34. PubMed ID: 17043644
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone G; Teofili L; Voso MT; Lübbert M
Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
[TBL] [Abstract][Full Text] [Related]
11. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation and cancer.
Das PM; Singal R
J Clin Oncol; 2004 Nov; 22(22):4632-42. PubMed ID: 15542813
[TBL] [Abstract][Full Text] [Related]
13. Reactivating the expression of methylation silenced genes in human cancer.
Karpf AR; Jones DA
Oncogene; 2002 Aug; 21(35):5496-503. PubMed ID: 12154410
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic targets in hematopoietic malignancies.
Claus R; Lübbert M
Oncogene; 2003 Sep; 22(42):6489-96. PubMed ID: 14528273
[TBL] [Abstract][Full Text] [Related]
15. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Conley BA; Wright JJ; Kummar S
Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
[TBL] [Abstract][Full Text] [Related]
16. Epigenome: a new target in cancer therapy.
Giacinti L; Vici P; Lopez M
Clin Ter; 2008; 159(5):347-60. PubMed ID: 18998037
[TBL] [Abstract][Full Text] [Related]
17. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy.
Christman JK
Oncogene; 2002 Aug; 21(35):5483-95. PubMed ID: 12154409
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy.
Grønbaek K; Treppendahl M; Asmar F; Guldberg P
Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):389-96. PubMed ID: 18947362
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation and gene silencing in cancer.
Baylin SB
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S4-11. PubMed ID: 16341240
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
